SILVER SPRING, MD — A US Food and Drug Administration (FDA) advisory panel has endorsed miltefosine capsules for the treatment of visceral, cutaneous, and mucosal leishmaniasis. Paladin's proposed ...

The FDA has approved Impavido (miltefosine; Paladin Therapeutics) for the treatment of three main types of leishmaniasis: visceral leishmaniasis, cutaneous leishmaniasis, and mucosal leishmaniasis in ...

MONTREAL, QUEBEC--(Marketwired - Mar 19, 2014) - Knight Therapeutics Inc. ("Knight") (TSX VENTURE:GUD) today announced that the U.S. Food and Drug Administration (FDA) has approved Impavido® ...

There are currently no other approved drugs to treatment cutaneous or mucosal leishmaniasis Profounda announced the launch of Impavido (miltefosine) for the treatment of visceral, mucosal, and ...

MONTREAL, QC--(Marketwired - March 22, 2016) - Knight Therapeutics Inc. (GUD.TO), through one of its wholly-owned subsidiaries ("Knight"), announced today that its U ...

The U.S. Food and Drug Administration today approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is a disease caused by Leishmania, a parasite which is ...

The new report entitled Leishmaniasis Treatment Market by Disease Type (Cutaneous Leishmaniasis, Mucosal Leishmaniasis, Visceral Leishmaniasis), Pathological Tests (Serological Tests, Parasitological ...

This is a preview. Log in through your library . Abstract We describe five cases of gastrointestinal leishmaniasis in patients with human immunodeficiency virus infection and review 10 additional ...

ARLINGTON, Va. - Driven by burgeoning ecotourism and military campaigns in Iraq and Afghanistan, a parasitic infection called leishmaniasis is showing up in more U.S. patients, often stumping doctors.